Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody

BURLINGAME, Calif., May 27 Epitomics, Inc., the rabbitmonoclonal antibody company, announced today that it has developed its 1000thnew rabbit monoclonal antibody. Each antibody has been created, tested andQC'd in house utilizing Epitomics' proprietary rabbit monoclonal antibodytechnology. "We are very excited to have reached this milestone in a shortperiod of time. This demonstrated the robustness of our technology anddevelopment pipeline," said Dr. Guo-Liang Yu, President and CEO of EpitomicsInc. "While thousands of antibodies exist in the market our Rabbit Monoclonalantibody technology has allowed for the development of monoclonal antibodiesthat were previously only possible to develop as a polyclonal antibody if atall," said Dr. Yu, "many of the targets for which we have developed a RabbitMonoclonal, no other monoclonal antibody had existed previously."

Epitomics is the exclusive provider of a proprietary method for makingmonoclonal antibodies from rabbits rather the conventional method of startingwith mice. The advantages of Epitomics' rabbit monoclonal antibodies(RabMAbs(TM)) include high specificity and affinity which provide excellentresults in a variety of commonly used immunoassays. "Each one of our rabbitmonoclonal antibodies undergoes stringent testing in five major immunoassaysincluding Western blotting, Immunohistochemistry, Immunofluorescence,Immunopreciptation and Flow Cytometry, before being released," said Dr. PeterLi, Senior VP of Product Development, "our rabbit monoclonals are among themost extensively characterized antibodies available." The complete list ofRabbit Monoclonals including background information and data for each antibodyis available for viewing on Epitomics website.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated todeveloping breakthrough monoclonal antibody technology for research,diagnostic and therapeutic applications. The Company utilizes a unique andproprietary RabMAb(TM) (Rabbit Monoclonal Antibody) technology which producesantibodies with superior binding affinity and bioactivity in a wide variety ofbiological assays. The Company is headquartered in Burlingame, California, andoperates a wholly owned subsidiary in Hangzhou, the People's Republic of China.More information about Epitomics can be found at http://www.epitomics.com

SOURCE Epitomics, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...